BEIJING, April 22 /PRNewswire-Asia-FirstCall/ -- Lotus Pharmaceuticals, Inc. (OTC Bulletin Board: LTUS) ("Lotus" or the "Company"), a growing developer, manufacturer and seller of medicine and drugs in the People's Republic of China (the "PRC"), today reported it will exhibit at the 63rd PHARMCHINA.
Time: April 24-26, 2010 Venue: International Convention Center, Xiamen Primary Booth: Liang Fang, Beijing Delegate Area
The Company has attended PHARMCHINA exhibitions every year since 1996 as a way to strengthen customer relationships and attract new distributors, while promoting its products.
Lotus will continue to market both its self-branded and self-produced drugs that have established market shares in China. Lotus will also introduce its upcoming innovative asthma drug Laevo-Bambutero, together with two other pipeline drugs Gliclazide-Controlled Release Tablets for type 2 diabetes and Isosorbide Mononitrate-Sustained Release Tablets for coronary artery disease.
PHARMCHINA has been the largest and most recognized exhibition in the Chinese pharmaceutical industry over the last thirty years. With a gross floor area of more than 60,000 square meters and leading professional and academic forums, it attracts more than 1,900 exhibitors. PHARMCHINA is a diversified trading and exchange platform for pharmaceutical companies. For more information, please see http://www.pharmchina.com.cn .
About Lotus Pharmaceuticals, Inc. ( http://www.lotuspharma.com )
Lotus Pharmaceuticals, Inc. is a growing developer and producer of drugs and a licensed national seller of pharmaceutical items in the PRC. Lotus operates its business through its two controlled entities: Liang Fang Pharmaceutical, Ltd. and En Ze Jia Shi Pharmaceutical, Ltd. Lotus' current drug development is focused on the treatment of cerebro-cardiovascular disease, asthma and diabetes. Liang Fang sells drugs directly and indirectly through its national sales channels to hospitals, clinics and drugs stores in 30 provinces of the PRC.
Lotus Pharmaceuticals, Inc. Yan ZENG, CFO Tel: +86-10-6389-9868 Email: firstname.lastname@example.org
|SOURCE Lotus Pharmaceuticals, Inc.|
Copyright©2010 PR Newswire.
All rights reserved